

Valeant Pharmaceuticals International, Inc.
 Form 4
 March 04, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Chai-Onn Robert Roswell

2. Issuer Name and Ticker or Trading Symbol
 Valeant Pharmaceuticals International, Inc. [VRX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
 2150 ST. ELZEAR BLVD. WEST
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 03/02/2015

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 EVP, CLO, General Counsel

LAVAL, A8 H7L 4A8

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock, no par value	03/02/2015		M		90,939 (1)	A	\$ 25.42 112,296 D
Common Stock, no par value	03/02/2015		S		90,939 (1)	D	\$ 200.0142 (2) 21,379 D
Common Stock, no par value	03/03/2015		M		21,808 (3)	A	\$ 6.1 43,187 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Underlying Security (Instr. 3 and 4)
Non-Qualified Stock Options (right to purchase)	\$ 25.42	03/02/2015		M	90,939 ⁽¹⁾	10/08/2014 ⁽⁴⁾ 11/11/2015	Common shares, no par value
Non-Qualified Stock Options (right to purchase)	\$ 6.1	03/03/2015		M	21,808 ⁽³⁾	11/01/2009 ⁽⁴⁾ 11/01/2015	Common shares, no par value

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Chai-Onn Robert Roswell 2150 ST. ELZEAR BLVD. WEST LAVAL, A8 H7L 4A8			EVP, CLO, General Counsel	

Signatures

by: Nicholas Zaroni for Robert
Chai-Onn

03/04/2015

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This number represents options exercised and sold pursuant to a 10b5-1 trading plan covering these options, which were to expire on November 11, 2015.
- (2) This number represents the weighted average sale price for all sales of common stock acquired upon exercise of options and sold, in each case pursuant to a 10b5-1 trading plan. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 4

issuer, the reporting person will provide full information regarding the number of shares sold at each price.

- (3) This number represents options exercised and held pursuant to a 10b5-1 trading plan covering these options, which were to expire on November 1, 2015.

- (4) The options vested one-fourth per year over four years starting with the first vest date falling on the first anniversary of the vesting commencement date, the second vest date falling on the second anniversary of the vesting commencement date, the third vest date falling on the third anniversary of the vesting commencement date, and the fourth vest date falling on the fourth anniversary of the vesting commencement date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.